Candel TherapeuticsCADL
CADL
About: Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Employees: 38
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
950% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 2
267% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 9
235% more capital invested
Capital invested by funds: $46.4M [Q3] → $156M (+$109M) [Q4]
103% more call options, than puts
Call options by funds: $9.79M | Put options by funds: $4.83M
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
35% more funds holding
Funds holding: 52 [Q3] → 70 (+18) [Q4]
21.35% more ownership
Funds ownership: 20.86% [Q3] → 42.2% (+21.35%) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
199%
upside
Avg. target
$21
318%
upside
High target
$25
398%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Vernon Bernardino 16% 1-year accuracy 11 / 70 met price target | 278%upside $19 | Buy Reiterated | 11 Apr 2025 |
Canaccord Genuity John Newman 7% 1-year accuracy 2 / 27 met price target | 398%upside $25 | Buy Maintained | 26 Feb 2025 |
Citigroup Yigal Nochomovitz 15% 1-year accuracy 6 / 41 met price target | 398%upside $25 | Buy Initiated | 20 Feb 2025 |
B of A Securities Alec Stranahan 0% 1-year accuracy 0 / 8 met price target | 199%upside $15 | Buy Initiated | 7 Feb 2025 |
Financial journalist opinion
Based on 7 articles about CADL published over the past 30 days
Neutral
GlobeNewsWire
19 hours ago
Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
NEEDHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that an abstract was accepted for an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 to June 3, 2025, in Chicago, IL. The oral presentation will feature data from the Company's phase 3 clinical trial of CAN-2409 in patients with intermediate-to-high risk localized prostate cancer.
Positive
Proactive Investors
3 weeks ago
Candel Therapeutics reveals new data showing better outcomes for glioma patients using CAN-2409
Candel Therapeutics Inc (NASDAQ:CADL) shared promising results from a Phase 1b clinical trial testing its experimental cancer therapy, CAN-2409, in patients with newly diagnosed high-grade glioma—a particularly aggressive form of brain cancer. The study, published in Neuro-Oncology, found that CAN-2409, when combined with the immunotherapy drug nivolumab and standard treatments like surgery, radiation, and chemotherapy, was well tolerated and showed signs of boosting the immune system's response to tumors.
Neutral
GlobeNewsWire
3 weeks ago
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients
Data published in Neuro-Oncology demonstrate promising safety profile and potential survival benefit when combining CAN-2409 and nivolumab with standard of care Data published in Neuro-Oncology demonstrate promising safety profile and potential survival benefit when combining CAN-2409 and nivolumab with standard of care
Positive
Proactive Investors
3 weeks ago
Candel Therapeutics reports breakthrough data for late-stage lung cancer – ICYMI
Candel Therapeutics Inc (NASDAQ:CADL) earlier this week shared updated clinical data from a Phase 2a study evaluating its immunotherapy candidate CAN-2409 in patients with advanced non-small cell lung cancer. The company said the study enrolled patients who had exhausted standard treatment options, including chemotherapy and checkpoint inhibitors.
Positive
Proactive Investors
4 weeks ago
Candel Therapeutics reports positive survival data for CAN-2409 in advanced lung cancer trial
Candel Therapeutics Inc (NASDAQ:CADL) said on Wednesday that its experimental immunotherapy, CAN-2409, demonstrated prolonged median overall survival in a Phase 2a clinical trial for patients with advanced non-small cell lung cancer (NSCLC) who had not responded to immune checkpoint inhibitors (ICI). Patients receiving CAN-2409 showed a median overall survival of 24.5 months, exceeding historical survival rates for this population, the company said.
Neutral
GlobeNewsWire
4 weeks ago
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment
NEEDHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced final survival data from a phase 2a clinical trial of CAN-2409 in patients with stage III/IV NSCLC, inadequately responding to ICI treatment. mOS was 24.5 months in 46 evaluable patients receiving 2 courses of CAN-2409 (per protocol population; cohort 1 and 2) and 21.5 months in evaluable patients from cohort 2 (n=41) that presented with progressive disease at baseline, despite ICI treatment. mOS in patients with progressive disease despite ICI treatment, was 9.8-11.8 months in other studies, including those with standard of care of docetaxel chemotherapy, which has a very poor prognosis, did not exceed 12 months in other published studies.(1, 2 ) This final analysis included extended follow-up data (1 year after the previous data cut) with a median follow up time for the per protocol population of 32.4 months. Data showed a sizable percentage of patients with survival exceeding 24 months, evidence of a long tail of survival, with 37% of patients with progressive disease despite treatment with ICI alive 2 years after CAN-2409 administration.
Negative
Zacks Investment Research
4 weeks ago
Bears are Losing Control Over Candel Therapeutics (CADL), Here's Why It's a 'Buy' Now
Candel Therapeutics (CADL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Positive
Proactive Investors
1 month ago
Candel Therapeutics partners with IDEA Pharma on commercialization of lead asset CAN-2409
Candel Therapeutics Inc (NASDAQ:CADL) announced that it has partnered with IDEA Pharma to advance the commercialization of its lead immunotherapy candidate CAN-2409. The collaboration follows positive Phase 3 data showing CAN-2409 significantly improved disease-free survival in patients with intermediate-to-high-risk localized prostate cancer.
Neutral
GlobeNewsWire
1 month ago
Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409
NEEDHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, together with IDEA Pharma, a Division of SAI MedPartners (IDEA), a pioneering biopharmaceutical strategy consultancy, today announced a strategic commercial partnership.
Positive
Proactive Investors
1 month ago
Candel Therapeutics appoints cancer immunology expert to research advisory board
Candel Therapeutics Inc (NASDAQ:CADL) said on Tuesday it has appointed Dr Elizabeth Jaffee to its research advisory board. Jaffee, an internationally recognized expert in cancer immunology and pancreatic cancer, currently serves as the Dana and Albert "Cubby" Broccoli Professor of Oncology and Deputy Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Charts implemented using Lightweight Charts™